These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 25667110)
1. Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project. Cary KC; Punnen S; Odisho AY; Litwin MS; Saigal CS; Cooperberg MR; Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):149-54. PubMed ID: 25667110 [TBL] [Abstract][Full Text] [Related]
2. Trends in the use of postprostatectomy therapies for patients with prostate cancer: a surveillance, epidemiology, and end results Medicare analysis. Sheets NC; Hendrix LH; Allen IM; Chen RC Cancer; 2013 Sep; 119(18):3295-301. PubMed ID: 23842985 [TBL] [Abstract][Full Text] [Related]
3. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. Elliott SP; Meng MV; Elkin EP; McAninch JW; Duchane J; Carroll PR; J Urol; 2007 Aug; 178(2):529-34; discussion 534. PubMed ID: 17570425 [TBL] [Abstract][Full Text] [Related]
4. Ascertainment of postprostatectomy radiotherapy for prostate cancer in the Surveillance, Epidemiology, and End Results database. Wang K; Sheets NC; Basak R; Chen RC Cancer; 2016 Oct; 122(19):3069-74. PubMed ID: 27352280 [TBL] [Abstract][Full Text] [Related]
5. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. Nieder AM; Porter MP; Soloway MS J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517 [TBL] [Abstract][Full Text] [Related]
6. Utilization trends in prostate cancer therapy. Kapoor DA; Zimberg SH; Ohrin LM; Underwood W; Olsson CA J Urol; 2011 Sep; 186(3):860-4. PubMed ID: 21788052 [TBL] [Abstract][Full Text] [Related]
7. A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age. Terakedis BE; Rossi PJ; Liauw SL; Johnstone PA; Jani AB Am J Clin Oncol; 2010 Dec; 33(6):619-23. PubMed ID: 20051808 [TBL] [Abstract][Full Text] [Related]
8. Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. Dinan MA; Robinson TJ; Zagar TM; Scales CD; Curtis LH; Reed SD; Lee WR; Schulman KA Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e781-6. PubMed ID: 22331001 [TBL] [Abstract][Full Text] [Related]
9. The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. Martin JM; Handorf EA; Kutikov A; Uzzo RG; Bekelman JE; Horwitz EM; Smaldone MC Cancer; 2014 Jul; 120(14):2114-21. PubMed ID: 24737481 [TBL] [Abstract][Full Text] [Related]
10. Determinants of the combined use of external beam radiotherapy and brachytherapy for low-risk, clinically localized prostate cancer. Quek RG; Master VA; Ward KC; Lin CC; Virgo KS; Portier KM; Lipscomb J Cancer; 2013 Oct; 119(20):3619-28. PubMed ID: 23913478 [TBL] [Abstract][Full Text] [Related]
11. Trends in the use of radical prostatectomy for treatment of prostate cancer. Ellison LM; Heaney JA; Birkmeyer JD Eff Clin Pract; 1999; 2(5):228-33. PubMed ID: 10623055 [TBL] [Abstract][Full Text] [Related]
12. Changes in prostate cancer incidence and treatment in USA. Lu-Yao GL; Greenberg ER Lancet; 1994 Jan; 343(8892):251-4. PubMed ID: 7905093 [TBL] [Abstract][Full Text] [Related]
13. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. Miller DC; Gruber SB; Hollenbeck BK; Montie JE; Wei JT J Natl Cancer Inst; 2006 Aug; 98(16):1134-41. PubMed ID: 16912266 [TBL] [Abstract][Full Text] [Related]
14. Variation in prostate cancer treatment associated with population density of the county of residence. Cary C; Odisho AY; Cooperberg MR Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):174-9. PubMed ID: 26782713 [TBL] [Abstract][Full Text] [Related]
15. A nationwide charge comparison of the principal treatments for early stage prostate carcinoma. Brandeis J; Pashos CL; Henning JM; Litwin MS Cancer; 2000 Oct; 89(8):1792-9. PubMed ID: 11042575 [TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537 [TBL] [Abstract][Full Text] [Related]
18. National trends in management of localized prostate cancer: A population based analysis 2004-2013. Chen J; Oromendia C; Halpern JA; Ballman KV Prostate; 2018 May; 78(7):512-520. PubMed ID: 29542178 [TBL] [Abstract][Full Text] [Related]
19. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303 [TBL] [Abstract][Full Text] [Related]
20. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR; Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]